1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Diabetes Drugs Market
2.2. Global Diabetes Drugs Market, By Therapy, 2023 (US$ Million)
2.3. Global Diabetes Drugs Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Diabetes Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Diabetes Drugs Market Vendors
3.2. Strategies Adopted by Diabetes Drugs Market Vendors
3.3. Key Industry Strategies
4. Diabetes Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Diabetes Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Insulin
5.3.2. Oral Hypoglycemic Drugs (anti-diabetes drugs)
5.3.3. Non-insulin Injectable Anti-diabetes Drugs
5.3.4. Others
5.3.5. Phase III (Market estimations by 2029)
5.3.5.1. ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)
5.3.5.2. ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)
5.3.5.3. Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)
5.3.5.4. Others
5.3.6. Tabular Presentation of Phase II (Qualitative Information)
5.3.7. Tabular Presentation of Phase Phase I (Qualitative Information)


6. North America Diabetes Drugs Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
6.3.Diabetes Drugs Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)

7. UK and European Union Diabetes Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
7.3.Diabetes Drugs Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)

8. Asia Pacific Diabetes Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
8.3.Diabetes Drugs Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)

9. Latin America Diabetes Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
9.3.Diabetes Drugs Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)

10. Middle East and Africa Diabetes Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
10.3.Diabetes Drugs Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Diabetes Drugs Market: By Therapy, 2022-2032, USD (Million)

11. Company Profile
11.1. AstraZeneca plc
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Biocon Limited
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Boston Therapeutics, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Cadila Healthcare
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Eli Lilly and Company
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. GlaxoSmithKline plc
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Johnson & Johnson
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Lupin Limited
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Merck & Co., Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Novartis International AG
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Pfizer Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Ranbaxy Laboratories Limited
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Sanofi S.A.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Takeda Pharmaceutical Company Ltd.
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives